v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 574,962 $ 632,138
Accounts receivable, net 54,605 138,624
Inventory 51,397 43,152
Prepaid expenses and other current assets 17,830 25,798
Government funding receivable 1,118 8,190
Total current assets 699,912 847,902
Property and equipment, net 162,900 52,694
Goodwill 326,029 283,668
Intangible assets, net 220,987 216,663
Deferred tax assets 0 765,799
Other assets 77,622 115,589
Total assets 1,487,450 2,282,315
Current liabilities:    
Accrued expenses and other current liabilities 60,237 53,371
Deferred revenue 3,360 3,088
Current portion of long-term debt 5,440 5,440
Current portion of finance lease liabilities 633 0
Total current liabilities 87,468 110,144
Long-term debt, less current portion 518,707 521,997
Finance lease liabilities, less current portion 31,897 0
Other long-term liabilities 59,494 68,975
Total liabilities 697,566 1,377,072
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Additional paid-in capital 128,503 137,898
Retained earnings 285,737 404,766
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc. 416,753 545,218
Non-controlling interest 373,131 360,025
Total stockholders’ equity 789,884 905,243
Total liabilities and stockholders’ equity 1,487,450 2,282,315
Class A Common Stock    
Stockholders’ equity:    
Common stock 1,322 1,317
Shares of Class B common stock    
Stockholders’ equity:    
Common stock 1,191 1,237
Nonrelated Party    
Current liabilities:    
Accounts payable 10,729 5,991
Related Party    
Current liabilities:    
Accounts payable 7,069 42,254
Payable to related parties pursuant to the Tax Receivable Agreement, less current portion $ 0 $ 675,956

Source

HTML PDF
ZIP